A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides

American Journal of Cardiology

Volumn 77, Issue 6, 1996, Pages B12-B16

  Ames, Richard P ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

BLOOD PRESSURE; CONFERENCE PAPER; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030030862     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)89233-8     Document Type: Conference Paper

References (38)

1. Ames, RP. The effects of antihypertensive drugs or serum lipids and lipoproteins. I. Diuretics. Drugs 1986;32:260-278.
2. Carlsen JC, Kober L, Torpe-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. Br Med J 1990;300:975-978.
3. Elliott WJ, Weber RR, Murphy MB. A double-blind, randomized, placebo-controlled comparison of the metabolic effects of low-dose hydrochlorothiazide and indapamide. J Clin Pharmacol 1991;31:751-757.
4. Burris JT, Weir MR, Oparil S, Weber M, Cady WJ, Steward WH. An assessment of diltiazem and hydrochlorothiazide in hypertension. JAMA 1990; 263:1507-1512.
5. Velussi M, Cernigol AM, Miniussi PM, Dapas F, Viezzoli L, Bernardi G, Rieppi, C, Caffau S. Treatment of mild to moderate hypertension with indapamide in type II diabetics: midterm (six months) evaluation. Curr Therap Res 1988;44:1076-1086.
6. Gerber A, Weidmann P, Bianchetti MG, Ferner C, Laederach K, Mordasini R, Riesen W, Bachman C. Serum lipoproteins during treatment with the antihypertensive agent indapamide. Hypertension 1985;7(suppl II):II-164-169.
7. Meyer-Sabellek W, Gotzen R, Heitz J, Arntz R, Schulte KL. Serum lipoprotein levels during long-term treatment of hypertension with indapamide. Hypertension 1985;7(suppl II):II-170-174.
8. Lacourciere Y. Analysis of well-being and 24-hour blood pressure recording in a comparative study between indapamide and captopril. Am J Med 1988; 84(suppl 1B):47-52.
9. Horgan JH, O'Donovan A, Teo KK. Echocardiographic evaluation of left ventricular function in patients showing an antihypertensive and biochemical response to indapamide. Postgrad Med J 1981;57(suppl 2):64-67.
10. Prisant LM, Beall SP, Nichoalds GE, Feldman EB, Carr AA, Feldman DS, Hames CG. Biochemical, endocrine, and mineral effects of indapamide in black women. J Clin Pharmacol 1990;30:121-126.
11. Kreeft H, Langlois S, Ogilvie RA. Comparative trial of indapamide and hydrochlorothiazide in essential hypertension, with forearm plethysmography. J Cardiovasc Pharmacol 1984;6:622-626.
12. Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M. Long-term experience with indapamide. Am Heart J 1983;106:258-262.
13. Cardona R, Lopez B, Fragachan F. Effects of indapamide on the lipid profile of patients with essential hypertension. In: Cardona R, ed. New Prospects in Hypertension. London: John Libbey, 1985:93-97.
14. Osei K, Holland G, Falko JM. Indapamide. Effects on apoprotein, lipoprotein, and glucoregulation in ambulatory diabetic patients. Arch Intern Med 1986;146:1973-1977.
15. Scalabrino A. Clinical investigations on long-term effects of indapamide in patients with essential hypertension. Curr Therap Res 1984;35:17-22.
16. Komajda M, Klimczak K, Boutin B, Brachman F, Guez D, Grosgogeat Y. Effects of indapamide on left ventricular mass and function in systemic hypertension with left ventricular hypertrophy. Am J Cardial 1990;65(suppl):37H-42H.
17. McVeigh GE, Dulie EB, Ravenscroft A, Galloway DB, Johnston GD. Low and conventional dose cyclopenthiazide on glucose and lipid metabolism in mild hypertension. Br J Clin Pharmacol 1989;27:523-526.
18. McKenney JM, Goodman RP, Wright Jr JT, Rifai W, Alycock DG, King ME. The effect of low-dose hydrochlorothiazide on blood pressure, serum potassium and lipoproteins. Pharmacotherapy 1986;6:179-184.
19. Vardan S, Mehrotra KG, Mookherjee S, Willsey GA, Gens JD, Green DE. Efficacy and reduced metabolic side effects of 15 mg chlorthalidone formulation in the treatment of mild hypertension. JAMA 1987;258:484-488.
20. Finnerty FA. Step-down treatment of mild systemic hypertension. Am J Cardiol 1984;53:1304-1307.
21. Lehtonen A, Gordin A, Salo H. Comparison of sustained release verapamil and hydrochlorothiazide in hypertension: effect on blood pressure and metabolic variable. Internat J Clin Pharmacol Ther Toxicol 1987;25:301-305.
22. Lacourciere Y, Gagne C. Influence of zofrenopril and low doses of hydrochlorothiazide on plasma lipoprotein in patients with mild to moderate essential hypertension. Am J Hypertension 1989;2:861-864.
23. Kohvakka A, Salo H, Gordin A, Eisolo A. Antihypertensive and biochemical effect of different doses of hydrochlorothiazide alone and in combination with triamterene. Acta Med Scand 1986;219:381-386.
24. Kochar MB, Landry KM, Ristow SM. Effects of reduction in doses and discontinuation of hydrochlorothiazide in patients with controlled essential hypertension. Arch Intern Med 1990;150:1009-1011.
25. Oberman A, Wassertheil-Smoller S, Langford HG, Blaufox MD, Davis BR, Blaszkowski T, Zimbaldi N, Hawkins M. Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk factors. Ann Intern Med 1990;112:89-95.
26. Pollare F, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-873.
27. Johnson BF, Saunders R, Hickler R, Marwahe R, Johnson J. The effects of thiazide diuretics upon plasma lipoproteins. J Hypertens 1986;4:235-239.
28. Ames RP. Hyperlipidemia in hypertension: causes and prevention. Am Heart J 1991;122:1219-1224.
29. Middeke M, Richter O, Schwandt P, Beck B, Holzgreve H. Normalization of lipid metabolism after withdrawal from antihypertensive long-term therapy with beta-blockers and diuretics. Atherosclerosis 1990;10:145-147.
30. Andersen B, Snorrason SP, Ragnarsson J, Hardarson T. Hydrochlorothiazide and potassium chloride in comparison with hydrochlorothiazide and amiloride in the treatment of hypertension. Acta Med Scand 1985;218:449-454.
31. Kaplan NM, Grundy S. Comparison of the effects of guanabenz and hydrochlorothiazide on plasma lipids. Clin Pharmacol Therap 1988;44:297-302.
32. Farsang C, Peter M, Balas-Eltes A, Feher J. Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension. J Cardiovasc Pharmacol 1987;10(suppl 12):S240-S243.
33. Distler A, Haerlin R, Hilgenstock G, Passfall J. Clinical aspects of antihypertensive therapy with urapidil. Comparison with hydrochlorothiazide. Drugs 1990; 40(suppl 4):21-27.
34. Stamler R, Stamler J, Gosch FC, Berkson DM, Dyer AR Hershinow P. Initial antihypertensive drug therapy. Final report of a randomized controlled trial comparing alpha-blocker and diuretic. Hypertension 1988;12:574-581.
35. Trost BN, Weidmann P, Riesen W, Claessens J, Streulens Y, Nelermans F. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension. Am J Cardiol 1987;59(suppl):99G-104G.
36. McVeigh G, Galloway D, Johnston D. The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide. Br Med J 1988;297:95-98.
37. Monmany J, Domingo R, Gomez JA, Sanz F, Roca-Cusacks A, Nolla J, Jane F. Effects of long-term treatment with metoprolol and hydrochlorothiazide on plasma lipids and lipoproteins. J Int Med 1990;228:323-331.
38. Ames RP, Kuritsky L. Does it differ from thiazides? In: Messerli FH, ed. Cardiovascular Drug Therapy, 2nd ed., Philadelphia: W. B. Saunders; (in press).